drugset
drugset / Trial / NCT00776074

A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.

NCT00776074 ↗

Phase 2 Completed 80 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the pharmacodynamics of leuprorelin gelatin free formulation (GF) to leuprorelin gelatin containing formulation (GC) in female subjects with uterine fibroids.

Timeline

Start
2006-06
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 3.75 mg Subcutaneous

Indications

leiomyoma